Episode Thumbnail
Episode 59  |  39:26 min

5 Most Common Problems With Your CAPA Process

Episode 59  |  39:26 min  |  11.07.2019

5 Most Common Problems With Your CAPA Process

00:00
00:00
This is a podcast episode titled, 5 Most Common Problems With Your CAPA Process. The summary for this episode is: What are the most common problems with the CAPA process? Today, frequent guest Mike Drues, president of Vascular Sciences and Jon are going to dive into that question and get you the answers you need and want. SOME OF THE HIGHLIGHTS OF THE SHOW INCLUDE: ● Why the CAPA process is such a big issue within the industry and why Jon wrote a column on it. ● What businesses are doing instead of focusing on CAPA and why this is one of the major problems with the process, as well as why a cross-functional team is vital. ● How a management review board can help when it comes to regulations, as well as the fine line between micromanagement and giving a company too much latitude when it comes to meetings with the management review board. ● Being reactive vs. being proactive. ● Why it’s important to respect, but not fear, the FDA. Mike also talks about who you should fear when it comes to liability. ● Thoughts on whether the CAPA is used too frequently or not frequently enough. ● Thoughts on establishing criteria and giving companies the responsibility to establish that criteria themselves. ● The root cause of problems with the CAPA process and what companies can do about it.
What are the most common problems with the CAPA process? Today, frequent guest Mike Drues, president of Vascular Sciences and Jon are going to dive into that question and get you the answers you need and want. SOME OF THE HIGHLIGHTS OF THE SHOW INCLUDE: ● Why the CAPA process is such a big issue within the industry and why Jon wrote a column on it. ● What businesses are doing instead of focusing on CAPA and why this is one of the major problems with the process, as well as why a cross-functional team is vital. ● How a management review board can help when it comes to regulations, as well as the fine line between micromanagement and giving a company too much latitude when it comes to meetings with the management review board. ● Being reactive vs. being proactive. ● Why it’s important to respect, but not fear, the FDA. Mike also talks about who you should fear when it comes to liability. ● Thoughts on whether the CAPA is used too frequently or not frequently enough. ● Thoughts on establishing criteria and giving companies the responsibility to establish that criteria themselves. ● The root cause of problems with the CAPA process and what companies can do about it.

More Episodes

Past, Present, Future State (and World) of Quality in the Medical Device Industry

Focusing on the Intent of the UDI Requirements from FDA's Final Guidance Doc

Addressing the 'Who, What, When' of Quality in the Medical Device Industry

Meet a Guru: Maryann Mitchell

Why Storytelling Matters for Medical Device Companies

A Breakthrough Device that Aims to Prevent Osteoporosis